外電引述世衛文件指 WTO專家對國藥集團疫苗部分副作用數據信心十分低
據《路透》引述一份文件指,,世衛(WHO)專家對內地國藥集團新冠疫苗(BBIBP-CorV)就一些疫苗接種者呈現副作用的數據信心十分低(very low confidence),但對疫苗保護效能整體而言有信心。
世衛免疫戰略諮詢專家組(SAGE)就國藥疫苗本周評估所準備的證據評核,涵蓋45個國家及司法管轄區成年人,及6,500萬劑已接種疫苗。專家審視有關數據,並就疫苗相關政策提供建議。
文件顯示,在完成接種兩劑疫苗後,多國第三階段臨床測試的有效率是78.1%,略低於中國早前公布的79.34%。文件指,對18至59歲成年人而言,非常有信心完成兩劑疫苗接種後,可預防感染新冠病毒。
不過,文件補充,就參與者共病症與併發症進行安全分析有限,源於第三階段臨床測試出現共病症與併發症的參與者數量較少。
文件指出,對60歲以上長者接種一至兩劑國藥疫苗後出現嚴重副作用風險的證據質素,信心十分低。文件進一步稱,對有共病症與併發症、有健康特別狀況的個人接種一至兩劑國藥疫苗後出現嚴重副作用風險的證據質素,信心十分低。
據《路透》報道,美國總統拜登屈服於美國民主黨議員及其他百多個國家的壓力,轉(車太)支持放棄新冠病毒疫苗知識產權專利,消息導致隔晚美國疫苗股受壓。消息夾擊下,國藥集團旗下國藥控股(01099.HK)今早(6日)低開1.6%報25.35元後,跌幅隨即擴大,早市曾跌15.2%,低見21.85元,半日收跌10.1%,報23.15元,成交2,982萬股,涉逾6.96億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.